New Signature for Predicting Bladder Cancer Outcomes
Author Information
Author(s): Li Yulei, Zhang Lulu, Xu Gang, Chen Jiajun, Zhao Keyuan, Li Mengyao, Jin Jing, Peng Chao, Wang Kaifang, Pan Shouhua, Zhu Ke
Primary Institution: Shaoxing People’s Hospital, Zhejiang, China
Hypothesis
The study aims to explore the role and prognostic value of reactive oxygen species (ROS)-related genes in bladder cancer (BLCA).
Conclusion
A prognostic signature based on 17 ROS-related genes was identified, which can predict overall survival and chemotherapy response in bladder cancer patients.
Supporting Evidence
- The prognostic signature was validated in the GSE13507 cohort.
- The signature was negatively associated with tumor mutational burden.
- High-risk patients showed greater chemotherapy sensitivity compared to low-risk patients.
- Eleven candidate small-molecule drugs were identified for treating bladder cancer.
Takeaway
Researchers found a new way to predict how bladder cancer patients will do based on certain genes related to oxygen in their bodies.
Methodology
The study used RNA sequencing and clinical data from The Cancer Genome Atlas (TCGA) to identify ROS-associated genes and developed a prognostic signature through various statistical analyses.
Limitations
The study is retrospective and requires validation through prospective trials.
Participant Demographics
Patients with bladder cancer from Shaoxing People’s Hospital, with no prior radiation or chemotherapy.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website